We are live on ! Find out more
EDIT icon

Editas Medicine

195 hedge funds and large institutions have $51M invested in Editas Medicine in 2025 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 44 increasing their positions, 61 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

97% more call options, than puts

Call options by funds: $668K | Put options by funds: $339K

6% less funds holding

Funds holding: 207195 (-12)

8.81% less ownership

Funds ownership: 61.84%53.03% (-8.8%)

21% less capital invested

Capital invested by funds: $64.8M → $51M (-$13.8M)

28% less repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 61

32% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 34

Holders
195
Holders Change
-12
Holders Change %
-5.8%
% of All Funds
2.61%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
23
Increased
44
Reduced
61
Closed
34
Calls
$668K
Puts
$339K
Net Calls
+$329K
Net Calls Change
+$321K
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$8.66M +$946K +643,256 +9%
BlackRock
2
BlackRock
New York
$7.76M -$908K -617,393 -8%
Morgan Stanley
3
Morgan Stanley
New York
$3.08M +$1.65M +1,118,298 +73%
UBS AM
4
UBS AM
Illinois
$3.02M +$2.1M +1,430,000 +122%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$2.26M +$199K +135,214 +7%
State Street
6
State Street
Massachusetts
$2.14M -$38.4K -26,111 -1%
Dimensional Fund Advisors
7
Dimensional Fund Advisors
Texas
$1.87M -$811K -551,035 -26%
Bank of America
8
Bank of America
North Carolina
$1.76M +$1.6M +1,084,483 +250%
Two Sigma Investments
9
Two Sigma Investments
New York
$1.45M -$587K -399,297 -24%
UBS Group
10
UBS Group
Switzerland
$1.41M +$149K +101,294 +9%
Two Sigma Advisers
11
Two Sigma Advisers
New York
$1.41M -$650K -442,000 -27%
Renaissance Technologies
12
Renaissance Technologies
New York
$1.2M -$615K -418,084 -29%
AQR Capital Management
13
AQR Capital Management
Connecticut
$1.18M -$72.8K -49,517 -5%
JP Morgan Chase
14
JP Morgan Chase
New York
$1.07M +$202K +137,207 +17%
Acadian Asset Management
15
Acadian Asset Management
Massachusetts
$869K +$822K +558,567 +289%
Charles Schwab
16
Charles Schwab
California
$794K +$113K +76,647 +13%
Northern Trust
17
Northern Trust
Illinois
$762K -$57.4K -39,044 -6%
Susquehanna International Group
18
Susquehanna International Group
Pennsylvania
$679K +$212K +144,413 +33%
Goldman Sachs
19
Goldman Sachs
New York
$658K -$1.79M -1,218,701 -68%
KCM
20
Kennedy Capital Management
Missouri
$611K -$3.08K -2,096 -0.4%
XT
21
XTX Topco
Cayman Islands
$551K +$545K +370,325 +353%
D.E. Shaw & Co
22
D.E. Shaw & Co
New York
$533K +$412K +280,185 +156%
Jane Street
23
Jane Street
New York
$430K -$1.03M -702,617 -65%
Stifel Financial
24
Stifel Financial
Missouri
$412K +$25.9K +17,629 +5%
N
25
Nuveen
North Carolina
$367K

EDIT Hedge Fund Activity: Q1 2025 in Review

195 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q1 2025, worth a combined $51M — down 21% from $64.8M a quarter earlier.

Sellers outnumbered buyers: 34 funds closed out of EDIT and 23 opened new positions — a net loss of 11 holders — while 61 trimmed existing stakes and 44 added.

The largest buyer was UBS AM, adding an estimated $2.1M. The largest seller was Millennium Management, cutting an estimated $3.62M.

  • 195 institutional investors held Editas Medicine (EDIT) as of Q1 2025, down from 207 in Q4 2024.
  • Funds reported $51M of Editas Medicine stock for Q1 2025, down 21% quarter-over-quarter.
  • 23 funds opened new Editas Medicine positions in Q1 2025 and 34 closed out, a net change of -11 holders.
  • The largest Editas Medicine buyer in Q1 2025 was UBS AM, an estimated $2.1M added.
  • The largest Editas Medicine seller in Q1 2025 was Millennium Management, an estimated $3.62M sold.

Based on aggregated 13F filings for Q1 2025.